SCHEMBL3205670

SCHEMBL3205670

CCCCc1nc(CO)c(Cl)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
GPR84 Q9NQS5 5/20 0.38
PARP1 P09874 1/20 0.36
TYMP P19971 1/20 0.35
GSK3B P49841 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7275316 0.80 ALDH1A1 (0.44) ALDH1A1MAPK1GPR84PARP1
SCHEMBL4356446 0.80 ALDH1A1 (0.42) ALDH1A1MAPK1GPR84PARP1GSK3B
SCHEMBL13384270 0.79 ALDH1A1 (0.39) ALDH1A1MAPK1GPR84PARP1TYMP
SCHEMBL9122617 0.79 ALDH1A1 (0.41) ALDH1A1MAPK1GPR84PARP1GSK3B
SCHEMBL27786276 0.78 TYMP (0.37) ALDH1A1MAPK1PARP1TYMPGSK3B
SCHEMBL7626256 0.77 ALDH1A1 (0.46) ALDH1A1MAPK1GPR84PARP1TYMP
SCHEMBL14743462 0.76 ALDH1A1 (0.44) ALDH1A1MAPK1GPR84PARP1TYMP
SCHEMBL27531476 0.75 ALDH1A1 (0.41) ALDH1A1MAPK1GPR84PARP1TYMP
SCHEMBL225 0.75 ALDH1A1 (0.41) ALDH1A1MAPK1GPR84PARP1GSK3B
SCHEMBL9081675 0.75 GPR84 (0.45) ALDH1A1MAPK1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1885714-B1 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK PHARMACEUTICALS (SI) 2014-01-15 EP claimed
US-20090176849-A1 Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives LEK PHARMACEUTICALS, D.D. (SI) 2009-07-09 US claimed
EP-1885714-A2 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK Pharmaceuticals D.D. (SI) 2008-02-13 EP claimed
WO-2006125592-A2 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK PHARMACEUTICALS D.D. (SI) 2006-11-30 WO claimed
US-20040147787-A1 Process for oxidation of alcohols MILLER ROSS A (US) 2004-07-29 US claimed
WO-2003006435-A1 PROCESS FOR OXIDATION OF ALCOHOLS MERCK & CO., INC. (US) 2003-01-23 WO claimed
EP-1885714-B1 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK PHARMACEUTICALS (SI) 2014-01-15 EP disclosed
US-8293776-B2 Compositions and methods for treating inflammatory conditions of the bowel THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-23 US disclosed
WO-2010017312-A1 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE BOWEL THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-02-11 WO disclosed
US-20100035852-A1 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE BOWEL THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-02-11 US disclosed
US-20090176849-A1 Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives LEK PHARMACEUTICALS, D.D. (SI) 2009-07-09 US disclosed
EP-1885714-A2 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK Pharmaceuticals D.D. (SI) 2008-02-13 EP disclosed
WO-2006125592-A2 PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES LEK PHARMACEUTICALS D.D. (SI) 2006-11-30 WO disclosed
WO-2003006435-A1 PROCESS FOR OXIDATION OF ALCOHOLS MERCK & CO., INC. (US) 2003-01-23 WO disclosed
EP-0540400-B1 Quinoline derivatives, useful as angiotensin II antagonists SYNTHELABO (FR) 1995-08-23 EP disclosed
US-5432283-A Substituted phenyl in 2 position; intermediates for drugs to treat hypertensive pathologies, cardiac, renal or pulmonary insufficiencies, and glaucoma SYNTHELABO (FR) 1995-07-11 US disclosed
US-5371227-A Quinoline derivatives, process for their preparation, and their therapeutic applications SYNTHELABO (FR) 1994-12-06 US disclosed
US-5338740-A Angiotensin II receptor antagonists PFIZER INC. (US) 1994-08-16 US disclosed
EP-0540400-A1 Quinoline derivatives, useful as angiotensin II antagonists SYNTHELABO (FR) 1993-05-05 EP disclosed
EP-0429257-A2 Indole derivatives GLAXO GROUP LIMITED (GB) 1991-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147787-A1 Process for oxidation of alcohols TPO, ADH1C, GPX4 ALDH1A1 68/4885MAPK1 2684/4885GPR84 3076/4885
US-20090176849-A1 Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives AGTR1, AGTR2, REN ALDH1A1 790/4885MAPK1 509/4885GPR84 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.